Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis.
In a double-blind double-placebo crossover study naproxen (500-750 mg daily) was found to be equivalent to phenylbutazone (400-600 mg daily) in the control of disease activity in 20 patients suffering from ankylosing spondylitis during a two times 5-week trial period. No serious side effects were observed during the trial period. Gastric complaints occurred twice as often under phenylbutazone as under naproxen.
D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000627:therapeutic use*; D010653:Phenylbutazone / Q000627:therapeutic use*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*
D009288:Naproxen; D010653:Phenylbutazone